An elevated PI3K/AKT signaling pathway has been shown to be advantageous in specific physiological processes relating to tissue regeneration; thus, inhibiting PTEN, a suppressor of this pathway, has emerged as a potential therapeutic approach for ischemia, neurodegenerative diseases, infection, and insulin-resistant metabolic disorders [11,12,13]. The gene discussed is AKT1; the disease is metabolic disease.